News

Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D),…
Read More...

Pfizer Inc. and Seagen Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers,…
Read More...

Cytovance Biologics, Inc. (Cytovance Biologics), a biopharmaceutical contract development and manufacturing organization (CDMO), and Phenotypeca Limited (Phenotypeca), a research and…
Read More...

Cancer Research UK and UCB announced a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The…
Read More...

Sandoz signed a Memorandum of Understanding (MOU) to build a new biologics production plant in Lendava, Slovenia. The Sandoz investment is expected to be at least USD 400 million,…
Read More...

Alnylam Pharmaceuticals, Inc. and Medison Pharma have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary,…
Read More...

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-264, a stem…
Read More...

Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced entry into…
Read More...

OPKO Health, Inc. announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD…
Read More...

Sun Pharmaceutical announced the successful completion of its acquisition of Concert Pharmaceuticals for the development of deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor,…
Read More...

Shorla Oncology (‘Shorla’) announced that the U.S. Food and Drug Administration (FDA) approved the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted, for review, the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat adults and adolescents aged…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics License Application (sBLA) for LEQEMBI™…
Read More...

Coherus BioSciences, Inc. announced that the U.S. Food and Drug Administration (“FDA”) approved a single-dose, prefilled autoinjector presentation of UDENYCA (pegfilgrastim-cbqv), a…
Read More...

Ipsen announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s…
Read More...

Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen) today announced the launch of the…
Read More...

Intellia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2002 for the…
Read More...

Avenue Therapeutics, Inc. announced that it has entered into an exclusive license agreement with AnnJi Pharmaceutical Co., Ltd. (“AnnJi”), a Taiwanese clinical-stage drug company, for…
Read More...

Chugai Pharmaceutical Co., Ltd. and Biofourmis announced that they have entered into a new partnership agreement for the continued development and real-world use of digital solutions to…
Read More...

Confo Therapeutic announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the…
Read More...